{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:32:54Z","timestamp":1772166774022,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR302220"],"award-info":[{"award-number":["NIHR302220"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pilot Feasibility Stud"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In between episodes of (hypo) mania and major depression, people with bipolar disorder can experience ongoing low mood or mood instability, and these may also be present as part of cyclothymic disorder. This is a phase II evaluation of an adapted form of behavioural therapy (STABILISE) for inter-episode bipolar symptoms. The study aims to establish the feasibility and acceptability of the therapy and research procedures, including an economic component, to inform a future definitive trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients will be randomised 1:1 to either Treatment as Usual (control arm) or Treatment as Usual plus STABILISE intervention (intervention arm). Follow up points will be at 14, 30 and 52\u00a0weeks post eligibility confirmation, with 30\u00a0weeks as the primary end point. We aim to recruit 60 individuals meeting diagnostic criteria for a Bipolar Spectrum Disorder, and reporting ongoing bipolar symptoms (low mood or mood instability) outside of a manic or severe depressive episode. Feasibility and acceptability will be examined through recruitment and retention rates, completion rates for the candidate primary outcome measures (PHQ9, ALS-SF, QoL.BD and BRQ) and feedback from participants on their experience of study participation and therapy. Proceeding to a definitive trial will be indicated if the following criteria are met: (i) trial participation is deemed, or can be made, sufficiently safe; (ii) recruitment rate indicates that larger-scale recruitment would be feasible (recruitment rate of at least two participants per month within at least one site, with mitigation plan if overall target sample size not met); (iii) for candidate primary outcome measure follow up data is available at 30\u00a0weeks from at least 75% of participants, or from between 55 and 74% with clear plan for improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study is a randomised, controlled feasibility trial that builds on an initial case series of the STABILISE approach. The findings will be used to establish whether a future, definitive trial is feasible and to refine the research procedures and therapy protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ISRCTN18207465. Registered 13th March 2024,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN18207465\" ext-link-type=\"uri\">https:\/\/www.isrctn.com\/ISRCTN18207465<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40814-025-01678-6","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:50:34Z","timestamp":1752137434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A study protocol for a randomized controlled feasibility trial of behavioural therapy for interepisode bipolar symptoms (STABILISE)"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3865-9743","authenticated-orcid":false,"given":"Kim","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barnaby D.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"O\u2019Mahen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rod S.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonieta","family":"Medina-Lara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"4","key":"1678_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.euroneuro.2005.04.011","volume":"15","author":"S Pini","year":"2005","unstructured":"Pini S, De Queiroz V, Pagnin D, Pezawas L, Angst J, Cassano GB, Wittchen HU. Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol. 2005;15(4):425\u201334.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10","key":"1678_CR2","doi-asserted-by":"publisher","first-page":"e2351","DOI":"10.1002\/brb3.2351","volume":"11","author":"J Simon","year":"2021","unstructured":"Simon J, Pari AA, Wolstenholme J, Berger M, Goodwin GM, Geddes JR. The costs of bipolar disorder in the United Kingdom. Brain and Behavior. 2021;11(10).","journal-title":"Brain and Behavior"},{"issue":"2","key":"1678_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1192\/bjp.bp.105.013870","volume":"189","author":"ES Paykel","year":"2006","unstructured":"Paykel ES, Abbott R, Morriss R, Hayhurst H, Scott J. Sub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder. Br J Psychiatry. 2006;189(2):118\u201323.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"1678_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1034\/j.1399-5618.2003.00048.x","volume":"5","author":"GM MacQueen","year":"2003","unstructured":"MacQueen GM, Marriott M, Begin H, Robb J, Joffe RT, Young LT. Subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder. Bipolar Disord. 2003;5(5):349\u201355.","journal-title":"Bipolar Disord"},{"issue":"46","key":"1678_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jbtep.2014.07.005","volume":"1","author":"A Gershon","year":"2015","unstructured":"Gershon A, Eidelman P. Inter-episode affective intensity and instability: predictors of depression and functional impairment in bipolar disorder. J Behav Ther Exp Psychiatry. 2015;1(46):14\u20138.","journal-title":"J Behav Ther Exp Psychiatry"},{"issue":"1\u20132","key":"1678_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jad.2003.09.009","volume":"85","author":"FJ Kochman","year":"2005","unstructured":"Kochman FJ, Hantouche EG, Ferrari P, Lancrenon S, Bayart D, Akiskal HS. Cyclothymic temperament as a prospective predictor of bipolarity and suicidality in children and adolescents with major depressive disorder. J Affect Disord. 2005;85(1\u20132):181\u20139.","journal-title":"J Affect Disord"},{"issue":"2","key":"1678_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/bdi.12376","volume":"18","author":"L Samalin","year":"2016","unstructured":"Samalin L, de Chazeron I, Vieta E, Bellivier F, Llorca PM. Residual symptoms and specific functional impairments in euthymic patients with bipolar disorder. Bipolar Disord. 2016;18(2):164\u201373.","journal-title":"Bipolar Disord"},{"issue":"6","key":"1678_CR8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1192\/bjp.bp.117.201335","volume":"211","author":"P Roux","year":"2017","unstructured":"Roux P, Raust A, Cannavo AS, Aubin V, Aouizerate B, Azorin JM, Bellivier F, Belzeaux R, Bougerol T, Cussac I, Courtet P. Associations between residual depressive symptoms, cognition, and functioning in patients with euthymic bipolar disorder: results from the FACE-BD cohort. Br J Psychiatry. 2017;211(6):381\u20137.","journal-title":"Br J Psychiatry"},{"issue":"271","key":"1678_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jad.2020.03.049","volume":"15","author":"S Stanislaus","year":"2020","unstructured":"Stanislaus S, Faurholt-Jepsen M, Vinberg M, Coello K, Kjaerstad HL, Melbye S, Sletved KS, Christensen EM, Frost M, Bardram JE, Kessing LV. Mood instability in patients with newly diagnosed bipolar disorder, unaffected relatives, and healthy control individuals measured daily using smartphones. J Affect Disord. 2020;15(271):336\u201344.","journal-title":"J Affect Disord"},{"issue":"4","key":"1678_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/archpsyc.65.4.386","volume":"65","author":"LL Judd","year":"2008","unstructured":"Judd LL, Schettler PJ, Akiskal HS, Coryell W, Leon AC, Maser JD, Solomon DA. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse\/recurrence. Arch Gen Psychiatry. 2008;65(4):386\u201394.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1678_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1192\/bjp.bp.115.173930","volume":"210","author":"M Alda","year":"2017","unstructured":"Alda M, McKinnon M, Blagdon R, Garnham J, MacLellan S, O\u2019Donovan C, Hajek T, Nair C, Dursun S, MacQueen G. Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. Br J Psychiatry. 2017;210(1):54\u201360.","journal-title":"Br J Psychiatry"},{"issue":"301","key":"1678_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jad.2021.12.112","volume":"15","author":"S Yilmaz","year":"2022","unstructured":"Yilmaz S, Huguet A, Kisely S, Rao S, Wang J, Baur K, Price M, O\u2019Mahen H, Wright K. Do psychological interventions reduce symptoms of depression for patients with bipolar I or II disorder? A meta-analysis Journal of affective disorders. 2022;15(301):193\u2013204.","journal-title":"A meta-analysis Journal of affective disorders"},{"key":"1678_CR13","first-page":"123","volume":"9","author":"L Mazzarini","year":"2017","unstructured":"Mazzarini L. The treatment of cyclothymia. The treatment of bipolar disorder: integrative clinical strategies and future directions. 2017;9:123.","journal-title":"The treatment of bipolar disorder: integrative clinical strategies and future directions"},{"issue":"6","key":"1678_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1037\/ccp0000654","volume":"89","author":"M Ciharova","year":"2021","unstructured":"Ciharova M, Furukawa TA, Efthimiou O, Karyotaki E, Miguel C, Noma H, Cipriani A, Riper H, Cuijpers P. Cognitive restructuring, behavioral activation and cognitive-behavioral therapy in the treatment of adult depression: a network meta-analysis. J Consult Clin Psychol. 2021;89(6):563.","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"1678_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/wps.20701","volume":"19","author":"P Cuijpers","year":"2020","unstructured":"Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92\u2013107.","journal-title":"World Psychiatry"},{"issue":"10047","key":"1678_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(16)31140-0","volume":"388","author":"DA Richards","year":"2016","unstructured":"Richards DA, Ekers D, McMillan D, Taylor RS, Byford S, Warren FC, Barrett B, Farrand PA, Gilbody S, Kuyken W, O\u2019Mahen H. Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a randomised, controlled, non-inferiority trial. The Lancet. 2016;388(10047):871\u201380.","journal-title":"The Lancet"},{"issue":"2","key":"1678_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/PRA.0000000000000142","volume":"22","author":"LM Weinstock","year":"2016","unstructured":"Weinstock LM, Melvin C, Munroe MK, Miller IW. Adjunctive behavioral activation for the treatment of bipolar depression: a proof of concept trial. J Psychiatr Pract. 2016;22(2):149\u201358.","journal-title":"J Psychiatr Pract"},{"issue":"10","key":"1678_CR18","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3390\/brainsci12101407","volume":"12","author":"K Wright","year":"2022","unstructured":"Wright K, Mostazir M, Bailey E, Dunn BD, O\u2019Mahen H, Sibsey M, Thomas Z. Adapted Behavioural activation for bipolar depression: a randomised multiple baseline case series. Brain Sci. 2022;12(10):1407.","journal-title":"Brain Sci"},{"key":"1678_CR19","unstructured":"Linehan M. Cognitive-behavioral treatment of borderline personality disorder.\u00a0New York, NY: Guilford press; 1993."},{"key":"1678_CR20","first-page":"217","volume":"25","author":"MA Swales","year":"2018","unstructured":"Swales MA, Dunkley C. Structuring the wider environment and the DBT Team. The Oxford Handbook of Dialectical Behaviour Therapy. 2018;25:217.","journal-title":"The Oxford Handbook of Dialectical Behaviour Therapy"},{"issue":"1","key":"1678_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.beth.2018.03.009","volume":"50","author":"CR DeCou","year":"2019","unstructured":"DeCou CR, Comtois KA, Landes SJ. Dialectical behavior therapy is effective for the treatment of suicidal behavior: A meta-analysis. Behav Ther. 2019;50(1):60\u201372.","journal-title":"Behav Ther"},{"key":"1678_CR22","unstructured":"Haktan\u0131r A, Callender KA. Meta-analysis of dialectical behavior therapy (DBT) for treating substance use. Research on education and psychology. 2020;4(Special Issue):74\u201387."},{"issue":"154","key":"1678_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.brat.2022.104122","volume":"1","author":"NK Ciesinski","year":"2022","unstructured":"Ciesinski NK, Sorgi-Wilson KM, Cheung JC, Chen EY, McCloskey MS. The effect of dialectical behavior therapy on anger and aggressive behavior: a systematic review with meta-analysis. Behav Res Ther. 2022;1(154): 104122.","journal-title":"Behav Res Ther"},{"issue":"1","key":"1678_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40345-023-00288-6","volume":"11","author":"BD Jones","year":"2023","unstructured":"Jones BD, Umer M, Kittur ME, Finkelstein O, Xue S, Dimick MK, Ortiz A, Goldstein BI, Mulsant BH, Husain MI. A systematic review on the effectiveness of dialectical behavior therapy for improving mood symptoms in bipolar disorders. International Journal of Bipolar Disorders. 2023;11(1):6.","journal-title":"International Journal of Bipolar Disorders"},{"key":"1678_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40345-021-00226-4","volume":"9","author":"K Wright","year":"2021","unstructured":"Wright K, Dodd AL, Warren FC, Medina-Lara A, Dunn B, Harvey J, Javaid M, Jones SH, Owens C, Taylor RS, Duncan D. Psychological therapy for mood instability within bipolar spectrum disorder: a randomised, controlled feasibility trial of a dialectical behaviour therapy-informed approach (the ThrIVe-B programme). International Journal of Bipolar Disorders. 2021;9:1\u20133.","journal-title":"International Journal of Bipolar Disorders"},{"key":"1678_CR26","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336.","journal-title":"Qual Life Res"},{"issue":"2","key":"1678_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013537","volume":"7","author":"KN Avery","year":"2017","unstructured":"Avery KN, Williamson PR, Gamble C, Francischetto EO, Metcalfe C, Davidson P, Williams H, Blazeby JM. Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies. BMJ Open. 2017;7(2): e013537.","journal-title":"BMJ Open"},{"key":"1678_CR28","doi-asserted-by":"crossref","unstructured":"Kahan BC, Hindley J, Edwards M, Cro S, Morris TP. The estimands framework: a primer on the ICH E9 (R1) addendum. BMJ. 2024;384.","DOI":"10.1136\/bmj-2023-076316"},{"key":"1678_CR29","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1678_CR30","unstructured":"First MB, Williams JB, Karg RS, Spitzer RL. Structured Clinical Interview for DSM-5 Disorders\u2013Research Version (SCID-5-RV). Arlington: American Psychiatric Assocation. 2014."},{"issue":"6","key":"1678_CR31","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.paid.2003.12.013","volume":"37","author":"MN Oliver","year":"2004","unstructured":"Oliver MN, Simons JS. The affective lability scales: development of a short-form measure. Personality Individ Differ. 2004;37(6):1279\u201388.","journal-title":"Personality Individ Differ"},{"issue":"9","key":"1678_CR32","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"1678_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1678_CR34","unstructured":"World Health Organization. ICD-11:\u00a0International classification of diseases\u00a0(11th revision).\u00a02022."},{"issue":"4","key":"1678_CR35","first-page":"287","volume":"4","author":"SA Julious","year":"2005","unstructured":"Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat J Appl Stat Pharm Ind. 2005;4(4):287\u201391.","journal-title":"Pharm Stat J Appl Stat Pharm Ind"},{"issue":"3","key":"1678_CR36","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1177\/0962280215588241","volume":"25","author":"AL Whitehead","year":"2016","unstructured":"Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016;25(3):1057\u201373.","journal-title":"Stat Methods Med Res"},{"issue":"12","key":"1678_CR37","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.sapharm.2021.06.004","volume":"17","author":"B Fylan","year":"2021","unstructured":"Fylan B, Tomlinson J, Raynor DK, Silcock J. Using experience-based co-design with patients, carers and healthcare professionals to develop theory-based interventions for safer medicines use. Res Social Adm Pharm. 2021;17(12):2127\u201335.","journal-title":"Res Social Adm Pharm"},{"key":"1678_CR38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561\u201371.","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"1678_CR39","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S0006-3223(96)00548-3","volume":"42","author":"EG Altman","year":"1997","unstructured":"Altman EG, Hedeker D, Peterson JL, Davis JM. The Altman self-rating mania scale. Biol Psychiat. 1997;42(10):948\u201355.","journal-title":"Biol Psychiat"},{"issue":"6","key":"1678_CR40","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/0028-3908(78)90022-9","volume":"17","author":"P Bech","year":"1978","unstructured":"Bech P, Rafaelsen OJ, Kramp P, Bolwig TG. The mania rating scale: scale construction and inter-observer agreement. Neuropharmacology. 1978;17(6):430\u20131.","journal-title":"Neuropharmacology"},{"issue":"7","key":"1678_CR41","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1399-5618.2010.00865.x","volume":"12","author":"EE Michalak","year":"2010","unstructured":"Michalak EE, Murray G, CREST. BD. Development of the QoL. BD: a disorder\u2010specific scale to assess quality of life in bipolar disorder. Bipolar Disord. 2010;12(7):727\u201340.","journal-title":"Bipolar Disord."},{"issue":"10","key":"1678_CR42","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092\u20137.","journal-title":"Arch Intern Med"},{"issue":"1","key":"1678_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jad.2012.10.003","volume":"147","author":"S Jones","year":"2013","unstructured":"Jones S, Mulligan LD, Higginson S, Dunn G, Morrison AP. The bipolar recovery questionnaire: psychometric properties of a quantitative measure of recovery experiences in bipolar disorder. J Affect Disord. 2013;147(1):34\u201343.","journal-title":"J Affect Disord"},{"key":"1678_CR44","unstructured":"Simon, J, Mayer, S. HEQ (Health Economics Questionnaire), Version 08\u201309\u20132016. Vienna: Department of Health Economics, Center for Public Health, Medical University of Vienna. 2016."},{"issue":"1","key":"1678_CR45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1037\/1040-3590.19.1.107","volume":"19","author":"MA Cyders","year":"2007","unstructured":"Cyders MA, Smith GT, Spillane NS, Fischer S, Annus AM, Peterson C. Integration of impulsivity and positive mood to predict risky behavior: development and validation of a measure of positive urgency. Psychol Assess. 2007;19(1):107.","journal-title":"Psychol Assess"},{"issue":"4","key":"1678_CR46","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.beth.2011.04.004","volume":"42","author":"RC Manos","year":"2011","unstructured":"Manos RC, Kanter JW, Luo W. The behavioral activation for depression scale\u2013short form: development and validation. Behav Ther. 2011;42(4):726\u201339.","journal-title":"Behav Ther"},{"issue":"1\u20133","key":"1678_CR47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.schres.2007.12.470","volume":"100","author":"MJ Byerly","year":"2008","unstructured":"Byerly MJ, Nakonezny PA, Rush AJ. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophr Res. 2008;100(1\u20133):60\u20139.","journal-title":"Schizophr Res"},{"key":"1678_CR48","doi-asserted-by":"crossref","unstructured":"Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, Petticrew M. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ. 2021;374.","DOI":"10.1136\/bmj.n2061"},{"key":"1678_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-017-2031-8","volume":"17","author":"M Sekhon","year":"2017","unstructured":"Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17:1\u20133.","journal-title":"BMC Health Serv Res"},{"key":"1678_CR50","unstructured":"European Union. Regulation (EU) 2016\/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data."},{"key":"1678_CR51","unstructured":"International Committee of Medical Journal Editors. Defining the role of authors and contributors. Available from: https:\/\/www.icmje.org\/recommendations\/browse\/roles-and-responsibilities\/defining-the-role-of-authors-and-contributors. Cited 2024 June 19."}],"container-title":["Pilot and Feasibility Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-025-01678-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40814-025-01678-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-025-01678-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T14:03:07Z","timestamp":1770127387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40814-025-01678-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1678"],"URL":"https:\/\/doi.org\/10.1186\/s40814-025-01678-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5223139\/v1","asserted-by":"object"}]},"ISSN":["2055-5784"],"issn-type":[{"value":"2055-5784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SPIRIT checklist as Additional file 1 has been deleted. Supplementary materials 1 to 4 has been updated accordingly to its correct files.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has received approval from the U.K. Health Research Authority Research Ethics Service (IRAS ID: 335983), and from all relevant local approval bodies. Potential participants will receive full information about the study before giving consent and will have opportunity at the screening call, and before and during the intake assessment, to ask questions and discuss the study. Researchers will be fully trained in taking informed consent, including assessment of capacity to consent where appropriate. Consent will be taken only from individuals with capacity to make an informed decision on their participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Sandra Bucci is a director and shareholder of CareLoop Health Ltd., a University of Manchester start-up to develop and market digital solutions for mental health problems, currently in schizophrenia and postnatal depression. Kim Wright occasionally receives payment in addition to her usual salary for delivery of workshops on psychological interventions for bipolar disorder to academic and healthcare organisations, and for consultation to CareLoop Health Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}